top of page

Blog


Metabolomics analysis may help ALS patients
Amid the devastating blow to ALS patients and ALS researchers delt by the funding lords we have an idea. Part of our research uncovered...
2 days ago1 min read
7 views


Another Incredible Year
A look back to the future in ALS research Twenty-twenty four was a busy year at NDR! We made incredible progress, but we still have far...
Dec 31, 20244 min read
38 views
0 comments
Top 10 ALS news stories of 2024
https://alsnewstoday.com/news/top-10-als-news-stories-2024/
Dec 31, 20241 min read
5 views
0 comments
Feeding tube best placed before major weight loss with ALS: Study
https://alsnewstoday.com/news/feeding-tube-best-placed-before-major-weight-loss-als/
Dec 31, 20241 min read
0 views
0 comments
Healthcare costs increase as ALS progresses, Biogen study finds
https://alsnewstoday.com/news/healthcare-costs-increase-als-progression-biogen-us-study/
Dec 31, 20241 min read
1 view
0 comments
THE EUROPEAN SOCIETY OF MEDICINE
Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach Siobhan P Ellison DVM PhD1
Jul 2, 20241 min read
35 views
0 comments


Clinical Trial FC-US-001
June 21, 2024 The last subjects for the clinical trial using FC-12738, affectionally called TVALA, had their final follow up visit on ...
May 22, 20242 min read
80 views


Richard H Helms 1949-2024
In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in...
May 22, 20242 min read
382 views
TVALA Drug Trial
We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study...
Mar 5, 20241 min read
41 views
0 comments
MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION
We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first...
Dec 19, 20232 min read
28 views
TVALA Fortune Journal
Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation
Dec 1, 20231 min read
41 views
0 comments
NDR starts clinical trial with TVALA
Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....
Aug 10, 20231 min read
42 views
NDR publishes novel study
The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...
Jan 24, 20231 min read
49 views
Congratulations to Dr. Susanne Petri and her team!
NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the...
Dec 8, 20221 min read
33 views
NDR awards Dr. Chandler Walker $1.1 Million for ALS Research
Dr. Chandler Walker, associate professor in the Department of Biomedical Sciences and Comprehensive Care at Indiana University School of ...
Nov 9, 20221 min read
50 views
Ghada Maged receives NDR student award
NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc....
Sep 29, 20221 min read
28 views


A Personal Message from Dr. Siddique
In this final installment, Dr. Siddique delivers a personal message.
Sep 16, 20221 min read
18 views


Second Video Installment
In this second installment, Dr. Siddique discusses the future of ALS research and its implications for researchers and patients. We hope...
Sep 12, 20221 min read
13 views


New Video Series
We're pleased to announce that Northwestern University-Feinberg School of Medicine has produced a three-part video series on ALS,...
Sep 7, 20221 min read
22 views
NDR's TVALA® Trademarked
The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for...
Aug 31, 20221 min read
144 views
bottom of page